Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M201Revenue $M3.1Net Margin (%)-987.6Z-Score-5.8
Enterprise Value $M137EPS $-1.1Operating Margin %-820.4F-Score3
P/E(ttm))0Cash Flow Per Share $-1.0Pre-tax Margin (%)-987.6Higher ROA y-yN
Price/Book3.210-y EBITDA Growth Rate %-31.0Quick Ratio5.2Cash flow > EarningsN
Price/Sales43.95-y EBITDA Growth Rate %-24.0Current Ratio5.2Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-86.3Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M62.2ROI % (ttm)-60.6Gross Margin Increase y-yY

Gurus Latest Trades with AGEN

Number of guru portfolios checked: 56.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AGENJean-Marie Eveillard 2014-03-31 Buy $2.64 - $5.1
($3.52)
$ 3.23-8%New holding, 200000 sh.200,000
AGENGeorge Soros 2014-03-31 Buy $2.64 - $5.1
($3.52)
$ 3.23-8%New holding, 102200 sh.102,200
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AGEN is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
AGEN Jean-Marie Eveillard 2014-03-31200,0000.320New Buy
AGEN George Soros 2014-03-31102,2000.160New Buy
Premium Most recent portfolio changes are included for Premium Members only!


AGEN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Wentworth KerryVP, Clinical, Reg & Qual 2014-02-26Sell5,000$5-35.4view
Valentine KarenVP General Counsel 2014-01-23Sell2,850$3.5-7.71view
Sharp ShaliniDirector 2013-01-30Sell288$4.36-25.92view
Sharp ShaliniDirector 2012-10-31Sell288$4.4-26.59view
Sharp ShaliniDirector 2012-08-29Sell288$4.64-30.39view

Press Releases about AGEN :

Quarterly/Annual Reports about AGEN:

News about AGEN:

Articles On GuruFocus.com
Agenus Inc.: Ingeniously Designed Vaccines To Galvanized Tomorrow's Medicine Jul 25 2014 
Agenus: Grossly Undervalued GlaxoSmithKline Acquisition Target Sep 10 2012 
5 Speculative Biotech Stocks to Consider Buying Now Jan 24 2012 
Weekly CEO Buys Highlight: CTAS, VRX, TAT, AGEN, MRK Aug 20 2011 
Chairman & CEO of Agenus Inc. (AGEN) Garo Armen Buys 2,150,976 Shares Aug 18 2011 
Antigenics Inc. Reports Operating Results (10-K) Mar 16 2011 
Antigenics Inc. Reports Operating Results (10-Q) Nov 09 2010 
Antigenics Inc. (AGEN) CFO Shalini Sharp sells 1,500 Shares Oct 28 2010 
Antigenics Inc. (AGEN) CFO Shalini Sharp sells 2,000 Shares Sep 14 2010 
Antigenics Inc. (AGEN) CFO Shalini Sharp sells 1,520 Shares Jul 28 2010 


More From Other Websites
Agenus Inc. (AGEN) Looks Strong as Stock Surges 11.15% Jul 25 2014
GSK seeks approval for world's first malaria vaccine Jul 24 2014
GSK seeks approval for world's first malaria vaccine Jul 24 2014
AGENUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 24 2014
Agenus Reports Second Quarter 2014 Financial Results Jul 24 2014
First Vaccine Candidate for Malaria is Accepted for EU Regulatory Review Jul 24 2014
Agenus to Report Second Quarter 2014 Financial Results on July 24, 2014; Conference Call to Follow Jul 17 2014
Agenus to Report Second Quarter 2014 Financial Results on July 24, 2014; Conference Call to Follow Jul 17 2014
Agenus Up on Positive Prophage Data Jul 02 2014
Regeneron Pharmaceuticals (REGN) Jumps: Stock Gains 7.4% Jul 02 2014
Agenus Inc. (AGEN) Soars: Stock Adds 10.3% in Session Jul 02 2014
Why Agenus (AGEN) Stock Is Spiking Today Jul 01 2014
AGENUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 01 2014
Agenus Brain Cancer Vaccine Shows Extended Survival in Phase 2 Final Data Analysis Jul 01 2014
Agenus brain cancer vaccine doubles survival rate in study Jul 01 2014
Agenus brain cancer vaccine nearly doubles survival rate in study Jul 01 2014
AGENUS INC Files SEC form 8-K, Change in Directors or Principal Officers Jun 30 2014
AGENUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 27 2014

Add Notes, Comments or Ask Questions

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide